EGFR and hereditary sensory and autonomic neuropathy: A case–control study revealed the main risk factors of CIP through prior lung disease, thoracic radiotherapy (RT), and combination treatment of ICIs or epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), with odds ratios (OR): 2.86, 3.34, and 2.73, respectively.18